drugset / Trial / NCT02680847

Safety and Pharmacokinetic Study of ALO-02 in Children Ages 7-17 With Pain

NCT02680847

Phase 4 Terminated 32 enrolled Pfizer
Open-labelTreatment

Summary

Safety and pharmacokinetics of an abuse-deterrent, extended-release formulation of oxycodone hydrochloride with a sequestered naltrexone core in children 7-17 with moderate-severe pain.

Timeline

Start
2016-01-21
Primary completion
2018-01-10
Completion
2018-01-24

Drugs

EvaluationDrugModalityDoseRoute
Subject ALO-02 Unknown Oral

Indications

No indication recorded.